pioglitazone has been researched along with Bacteremia in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Bacteremia: The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miyazaki, H | 1 |
| Kinoshita, M | 1 |
| Nakashima, H | 1 |
| Nakamura, S | 1 |
| Saitoh, D | 1 |
1 other study available for pioglitazone and Bacteremia
| Article | Year |
|---|---|
Pioglitazone Modifies Kupffer Cell Function and Protects against
Topics: Animals; Bacteremia; Escherichia coli; Escherichia coli Infections; Hypoglycemic Agents; Kupffer Cel | 2022 |